|

NY-ESO-1 TCR/IL-15 NK Clinical Trials

2 actively recruiting trials across 1 location

Pipeline

Phase 1: 1Phase 1/2: 1

Top Sponsors

  • M.D. Anderson Cancer Center2

Indications

  • Cancer2
  • Myxoid/Round Cell Liposarcoma1
  • Synovial Sarcoma1
  • Myeloma1

Houston, Texas2 trials

Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma

M D Anderson Cancer Center

Phase 1/2
Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1

MD Anderson Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.